Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Pegylated Liposomal Doxorubicin-related Palmar-plantar Erythrodysesthesia ('hand-foot' Syndrome).
D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti, G. Scambia
Published 2007 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome or hand-to-foot syndrome, is a distinctive and relatively frequent dermatologic toxic reaction associated with certain chemotherapeutic agents. Pegylated liposomal doxorubicin (PLD), a long-circulating formulation of doxorubicin in which doxorubicin hydrochloride is encapsulated within pegylated liposomes, is approved to treat patients with metastatic breast cancer, advanced ovarian cancer, and acquired immunodeficiency syndrome-related Kaposi's sarcoma. The incidence of PPE is increased in patients receiving PLD compared with conventional doxorubicin. In studies that utilized the currently approved dose of PLD (50 mg/m(2) every 4 weeks), approximately 50% of all patients receiving PLD experienced PPE, and approximately 20% experienced grade 3 PPE. The pathophysiology of PPE, as it occurs with any drug with which it is associated, is not well understood. Studies evaluating the development of PPE specifically associated with PLD have not fully elucidated the mechanism; however, data support the roles of drug excretion in sweat and local pressure as contributors. When PPE develops, clinical interventions with respect to altering PLD administration include dose reduction, less frequent dosing, and ultimately, drug withdrawal with several consequences on treatment efficacy. This article will review the available data regarding the etiology and potential management strategies of PPE associated with PLD.
This paper references
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
P. Rose (2001)
Chemotherapy-induced palmer planter erythrodysesthesia.
S. Bhasin (2005)
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity
D Lorusso (2004)
Protective effect of amifostine (AMF) on Doxil/Caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients (pts) with advanced cancer
O Lyass (2001)
Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
R. Drake (2004)
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
S. Campos (2001)
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
D. Lorusso (2004)
[Hand-foot syndrome with capecitabine therapy].
A. Marini (2007)
Use of ‘Bag Balm’ as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents
SF Chin (2001)
Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone
MA Titgan (1997)
The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
K. Molpus (2004)
Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
D. Vail (1998)
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
C. Eng (2001)
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
J. Lokich (1984)
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma
R. Rifkin (2006)
Effect of celecoxib on capecitabine-indiced hand-foot syndrome and antitumor activity. Oncology (Williston
E Lin (2002)
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
A. López (1999)
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
M. Amantea (1999)
Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.
G. Ellis (2002)
Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.
G. Bertelli (1995)
Vitamin B6 and Skin Lesions in Rats
P. György (1939)
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
J. Sehouli (2006)
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion
C. Fabian (2004)
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
E. Lin (2002)
Hand-Fuß-Syndrom bei einem Patienten unter Capecitabin-Therapie
A. Marini (2006)
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
M. Markman (2000)
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
U. Jacobi (2005)
Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment.
A. Comandone (1993)
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity
G. Charrois (2003)
Erythematous eruption of the palms and soles associated with mitotane therapy.
R. Zuehlke (1974)
Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer.
S. J. Edwards (2003)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)
Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome
E. Nagore (2000)
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
This paper is referenced by
Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children.
D. Hong (2014)
Applications of Piezoelectricity in Nanomedicine
G. Ciofani (2012)
Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma.
J. Kucharz (2019)
Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Y. Lu (2016)
Improving Anticancer Therapy with ELP-based Drug Delivery Systems
Eric M Mastria (2016)
A mini review on Oral dosage forms
P. Gayathri (2016)
Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.
S. Cai (2010)
Pegylated Liposomal Doxorubicin in the Management of Ovarian Cancer
G. Ferrandina (2010)
Bridging cancer biology and the patients' needs with nanotechnology-based approaches.
N. Fonseca (2014)
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency
Christina E. M. Schindler (2019)
Pegylated liposomal doxorubicin-induced miliaria crystallina and lichenoid follicular eruption
A. C. Seghers (2018)
Skin toxicity of anti‐cancer therapy
J. Ulrich (2008)
Nanocarriers as an emerging platform for cancer therapy.
D. Peer (2007)
Reviews in Oncology Capecitabine Associated Hand-Foot Syndrome : A Review
E. U. Cidon (2010)
Hauttoxizität durch antitumorale Therapie
J. Ulrich (2008)
Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
Y. Su (2017)
Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer
O. Kubeček (2019)
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
A. Templeton (2014)
Hand Problems Related to Chemotherapeutic Agents.
Beatrice L. Grasu (2015)
Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management.
Abeer Najem (2014)
Syndrome mains-pieds : nouvel effet secondaire de l’erlotinib
A. Rouxel (2008)
Challenges and Opportunities of Nanotechnology as Delivery Platform for Tocotrienols in Cancer Therapy
Geetha Maniam (2018)
The role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLD.
Jie Yang (2017)
We detail the arsenal of nanocarriers and molecules available for selective tumour targeting , and emphasize the challenges in cancer treatment
D. Peer (2007)
Liposome and immune system interplay: Challenges and potentials.
Fahimeh Zahednezhad (2019)
Efficient Prevention Strategy against the Development of a Palmar-Plantar Erythrodysesthesia during Chemotherapy
J. Lademann (2013)
Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
L. M. Kaminskas (2012)
Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma.
Eric M Mastria (2015)
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer.
A. Shafei (2017)
Hand-foot syndrome related to liposomal doxorubicin.
K. Swenson (2010)
Evaluation of cytotoxicity profile and intracellular localisation of doxorubicin-loaded chitosan nanoparticles
Gabriele Dadalt Souto (2016)
Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals.
B. Børresen (2018)See more